Meda buys respiratory focused Acton for up to $200m
This article was originally published in Scrip
Executive Summary
Swedish firm Meda has agreed to buy respiratory-focused Acton Pharmaceuticals of the US for up to $200m in an all cash transaction. The deal would bring Meda the US FDA-approved asthma treatment Aerospan (flunisolide), which privately-held Acton licensed from Forest Laboratories.